[1]刘晓秋,沈秀,王芹,等.尼可胺在大鼠体内的药代动力学研究[J].国际放射医学核医学杂志,2013,37(5):265-268.[doi:10.3760/cma.j.issn.1673-4114.2013.05.003]
　LIU Xiao-qiu,SHEN Xiu,WANG Qin,et al.Study on pharmacokinetics of NiKeAn in rat[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(5):265-268.[doi:10.3760/cma.j.issn.1673-4114.2013.05.003]
点击复制

尼可胺在大鼠体内的药代动力学研究(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
37
期数:
2013年第5期
页码:
265-268
栏目:
论著
出版日期:
2013-09-25

文章信息/Info

Title:
Study on pharmacokinetics of NiKeAn in rat
作者:
刘晓秋;  沈秀;  王芹;  龙伟;  王浩;  周则卫
300192 天津, 中国医学科学院放射医学研究所, 天津市分子核医学重点实验室
Author(s):
LIU Xiao-qiu;  SHEN Xiu;  WANG Qin;  LONG Wei;  WANG Hao;  ZHOU Ze-wei
Tianjin Key Laboratory of Molecular Nuclear Medicine, Institute of Radiation Medicine, Chinese Academy of Medical Sciences, Tianjin 300192, China
关键词:
辐射增敏药; 烟酰胺; 色谱法; 高压液相; 药代动力学; 大鼠
Keywords:
Radiation-sensitizing agents; Niacinamide; Chromatography;  high pressure liquid; Pharmacokinetics; Rats
DOI:
10.3760/cma.j.issn.1673-4114.2013.05.003
摘要:
目的 采用高效液相色谱法(HPLC)研究尼可胺在大鼠体内的药代动力学变化。方法 色谱柱为Sino chrom BDS柱(250 mm×4.6 mm,5μm),流动相为甲醇-0.02%醋酸(10:90),检测波长为260 nm,柱温为30℃,流速为1 ml/min,进样量为5 μl.通过大鼠眼底静脉取血,血浆经乙腈沉淀蛋白,测定尼可胺血药浓度,通过DAS2.0计算其药代动力学参数。结果 尼可胺的线性范围:20~1000 μg/ml (r=0.9998)。当尼可胺在大鼠血浆中的浓度为50、150和500 μg/ml时,提取回收率分别为84.9%、81.9%和79.1%,批内精密度和批间精密度均<5%.当大鼠给予125 mg/kg的尼可胺后,其主要药代动力学参数为:消除相半衰期(t1/2β)为(32.99±23.14)min,血药-时间浓度曲线下面积(AUC)(0-t)为(14390.23±2584.02)mg·L-1·min,AUC(0-∞)为(16569.89±3450.31) mg·L-1·min,达峰时间(Tmax)为(27.0±6.7) min,药峰浓度(Cmax)为(242.13±33.89) mg/L.当大鼠给予250 mg/kg的尼可胺后,其主要药代动力学参数为:t1/2β为(59.05±16.34)min,AUC(0-t)为(26752.23±7967.03)mg·L-1·min,AUC(0-∞)为(35812.87±9476.48) mg·L-1·min,Tmax为(27.5±11.3)min,Cmax为(316.32±63.68) mg/L.当大鼠给予500mg/kg的尼可胺后,其主要药代动力学参数为:t1/2β为(69.06±0.62) min,AUC(0-t)为(77306.48±27878.03)mg·L-1·min,AUC(0-∞)为(88014.22±26960.89)mg·L-1·min,Tmax为(40.0±7.7) min,Cmax为(601.42±147.150) mg/L。结论 HPLC操作简便、准确、灵敏度高、重现性好,能够用于尼可胺在大鼠体内的药代动力学研究,为人体内尼可胺的药代动力学研究提供了参考。
Abstract:
Objective To develop a sensitive and specific high performance liquid chro matography (HPLC) method for determination of NiKeAn in rat plasma, and study the Pharmacokinetics in rat.Methods Sino chrom BDS column (250 mm×416 mm, 5 μm) was used.The mobile phase was CH3OH-0.02%-phosphoric acid(10:90)with a flow rate of 1.0 ml/min, and the detection wave length was at 260 nm and 30℃ column temperature.The plasma was analyzed after a simple protein precipitation procedure with acetonitrile.The blood sample was collected from retinal vein and involved protein precipitation with acetonitrile.Concentration of NiKeAn in rat blood was analyzed by the established method, and the pharmacokinetics parameters were calculated by the DAS2.0 software.Results The linear range of NiKeAn in rat plasma was 20-1000 μg/ml (r=0.9998).As concentration of NiKeAn in rat plasma were 50, 150 and 500 μg/ml, the relative standard deviation of intra-batch and inter-batch were both less than 5.0%.The recovery rates of NiKeAn were 84.9%, 81.9% and 79.1%, respectively.After single dose of 125 mg/kg in rat, the main pharmacokinetic parameters were estimated to be as follows:elimination half-life time (t1/2β) was (32.99±23.14)min, the area under the curve (AUC)(0-t) was (14390.23±2584.02)mg·L-1·min, AUC(0-∞) was (16569.89±3450.31)mg·L-1·min, the time of peak (Tmax) was (27.0±6.7)min, the peak concentration of drug (Cmax) was (242.13±33.89)mg/L.After single dose of 250 mg/kg in rat, the main pharmacokinetic parameters were estimated to be as follows:t1/2β was (59.05±16.34)min, AUC(0-t) was (26752.23 ±7967.03) mg·L-1·min, AUC(0-∞) was (35812.87 ±9476.48) mg·L-1·min, Tmax was (27.5±11.3) min, Cmax was (316.32±63.68) mg/L.After single dose of 500 mg/kg in rat, the main pharmacokinetic parameters were estimated to be as follows:t1/2β was (69.06±0.62)min, AUC(0-t) was (77306.48±27878.03) mg·L-1·min, AUC(0-∞) was (88014.22±26960.89) mg·L-1·min, Tmax was(40.0±7.7) min, Cmax was(601.42±147.15) mg/L.Conclusions The operation of established HPLC approach was simple, accurate, high-sensitive and better reproducible.This study provides a better reference for pharmacokinetics of NiKeAn in human bodies.

参考文献/References:

[1] Fenton BM, Lord EM, Paoni SF. Enhancement of tumor perfusion and oxygenation by carbogen and nicotinamide during single-and multifraction irradiation. Radiat Res, 2000, 153(1):75-83.
[2] Janssens GO, Rademakers SE, Terhaard CH, et al. Accelerated radiotherapy with carbogen and nicotinamide for laryngeal cancer:results of a phase Ⅲ randomized trial. J Clin Oncol, 2012, 30(15):1777-1783.
[3] Sharma PK, Dwarakanath BS, Varshney R. Radiosensitization by 2-deoxy-D-glucose and 6-aminonicotinamide involves activation of redox sensitive ASKl-JNK/p38MAPK signaling in head and neck cancer cells. Free Radic Biol Med, 2012, 53(7):1500-1513.
[4] 王桂亮,刘晓秋,沈秀,等.尼可胺对H22肝癌荷瘤小鼠的放射增敏作用.天津医药,2011,39(5):442-444.
[5] 《化学药物非临床药代动力研究技术指导原则》课题研究组.化学药物非临床药代动力学研究技术指导原则.3版.北京:中国医药科技出版社,2005:133-144.
[6] 刘奕芳,沈维敏,沈杰,等.人血浆中茶碱和多索茶碱的HPLC法测定.中国医药工业杂志,2010,41(2):131-133.
[7] 姚瑶,丁从珠,葛卫红.高效液相色谱法测定甲氨蝶呤对来氟米特在大鼠体内药动学的影响.中国医院药学杂志,2012,32(23):1929-1931.

相似文献/References:

[1]霍小东,王慧星,阎卫亮,等.血管内皮抑制素对125I近距离照射裸鼠肺癌移植瘤的增敏效应研究[J].国际放射医学核医学杂志,2016,40(5):357.[doi:10.3760/cma.j.issn.1673-4114.2016.05.006]
　Huo Xiaodong,Wang Huixing,Yan Weiliang,et al.Sensitization effect of endostatin for 125I brachytherapy on transplanted tumor in nude mice[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):357.[doi:10.3760/cma.j.issn.1673-4114.2016.05.006]
[2]黄少祥,樊体强.塞来昔布对非小细胞肺癌移植瘤的辐射增敏实验研究[J].国际放射医学核医学杂志,2013,37(3):150.[doi:10.3760/cma.j.issn.1673-4114.2013.03.006]
　HUANG Shao-xiang,FAN Ti-qiang.Radiosensitization on non-small cell lung cancer induced by celecoxib[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(5):150.[doi:10.3760/cma.j.issn.1673-4114.2013.03.006]
[3]李卫红,王浩,周晓靓,等.肿瘤放射治疗增敏剂研究新进展[J].国际放射医学核医学杂志,2013,37(4):233.[doi:10.3760/cma.j.issn.1673-4114.2013.04.011]
　LI Wei-hong,WANG Hao,ZHOU Xiao-liang,et al.Radiosensitizers development and the pathways[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(5):233.[doi:10.3760/cma.j.issn.1673-4114.2013.04.011]
[4]李玉,董丹,阎英.肿瘤辐射增敏机制研究进展[J].国际放射医学核医学杂志,2007,31(1):48.
　LI Yu,DONG Dan,Yah Ying.The development of radiosensitizer mechanisms[J].International Journal of Radiation Medicine and Nuclear Medicine,2007,31(5):48.
[5]顾菲,刘晓秋.肿瘤辐射增敏的分子机制[J].国际放射医学核医学杂志,2006,30(5):298.
　GU Fei,LIU Xiao-qiu.The molecular mechanism of tumor radiosensitizer[J].International Journal of Radiation Medicine and Nuclear Medicine,2006,30(5):298.
[6]张渊琪,赵德善.分化型甲状腺癌的治疗进展[J].国际放射医学核医学杂志,2017,41(2):126.[doi:10.3760/cma.j.issn.1673-4114.2017.02.009]
　Zhang Yuanqi,Zhao Deshan.Advances in the treatment of differentiated thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2017,41(5):126.[doi:10.3760/cma.j.issn.1673-4114.2017.02.009]
[7]李美佳,沈瑜.烟酰胺和Carbogen气体用于肿瘤放射治疗临床应用前景[J].国际放射医学核医学杂志,1995,19(2):86.
[8]董正川,段玉清,樊赛军,等.新型辐射增敏药RRx-001[J].国际放射医学核医学杂志,2017,41(3):214.[doi:10.3760/cma.j.issn.1673-4114.2017.03.011]
　Dong Zhengchuan,Duan YuQing,Fan Saijun,et al.A novel radiosensitizer RRx-001[J].International Journal of Radiation Medicine and Nuclear Medicine,2017,41(5):214.[doi:10.3760/cma.j.issn.1673-4114.2017.03.011]
[9]刘晓秋,周则卫,沈秀,等.放射增敏剂尼可胺对Wistar大鼠致畸作用的研究[J].国际放射医学核医学杂志,2013,37(2):81.[doi:10.3760/cma.j.issn.1673-4114.2013.02.005]
　LIU Xiao-qiu,ZHOU Ze-wei,SHEN Xiu,et al.Study on teratogenicity of Nikean in Wistar rats[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(5):81.[doi:10.3760/cma.j.issn.1673-4114.2013.02.005]

备注/Memo

备注/Memo:
收稿日期:2012-07-11。
基金项目:天津市科技计划项目(09ZCKFSH01500)
通讯作者:周则卫,Email:zhouzewei@irm-cams.as.cn
更新日期/Last Update: 1900-01-01